- Undergraduate - New York University, Biology
- Medical School - New York University
- Graduate School - Harvard University

Joseph Merola, M.D., M.M.Sc.
- Mary Kay Inc. Distinguished Chair in Dermatology
- Dermatology - General
- Psoriasis, Psoriatic Arthritis, and Spondyloarthritis
- Connective Tissue Disease
Biography
Joseph F. Merola, M.D., M.M.Sc., is Professor and Chair of the Department of Dermatology, Professor of Internal Medicine in the Division of Rheumatic Diseases, and Professor in the Peter O’Donnell Jr School of Public Health at UT Southwestern Medical Center. He holds the Mary Kay Inc. Distinguished Chair in Dermatology. He’s an international expert in psoriasis and psoriatic arthritis; connective tissue diseases, including lupus and dermatomyositis; and complex medical dermatology, including atopic dermatitis requiring systemic therapy.
Dr. Merola earned his medical degree at the New York University School of Medicine and his Master of Medical Sciences at Harvard Medical School. He completed an internship in internal medicine at the Hospital of the University of Pennsylvania, followed by a residency in dermatology at New York University Medical Center, where he was Chief Resident. He continued with a residency in internal medicine and a fellowship in rheumatology at the Brigham and Women’s Hospital and Harvard Medical School.
One of only a handful of physicians in the country who are triple board-certified in dermatology, internal medicine, and rheumatology, Dr. Merola joined the UT Southwestern faculty in 2023.
Previously, he was Vice Chair of Dermatology and Founding Director of the Unit for Clinical Trials and Innovation at the Brigham and Women’s Hospital, where he also directed the Center for Skin and Related Musculoskeletal Diseases.
At UT Southwestern, Dr. Merola is the Director of Clinical Trials and Innovation and continues clinical translational research in inflammatory and autoimmune skin disease, pharmacoepidemiology, and the development of novel outcome measures, including digital health measures for use in both clinical research and clinical care.
He serves as the founding President of the Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) Consortium. He is also the current President of the Medical Dermatology Society (MDS), Treasurer and board member of the International Dermatology Outcome Measures Group (IDEOM), and President-Elect of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Additionally, he is a member of the medical and scientific boards of the National Psoriasis Foundation and the Lupus Foundation of America, and President-Elect of the Rheumatologic Dermatology Society.
Dr. Merola is also a member of the International Eczema Council and the International Psoriasis Council. He’s served on multiple national committees, including the Guidelines Committee for the American Academy of Dermatology.
He has published more than 300 peer-reviewed publications and received numerous awards, including the National Psoriasis Foundation’s Outstanding Educator Award, the Winter Clinical Educator of the Year Award, the Brigham and Women’s Hospital Distinguished Clinician Award, and the Mass General Brigham Pillars of Excellence Award in Research Leadership. He was named one of Boston’s Top Doctors for nearly a decade.
Dr. Merola will be honored in 2024 at the National Psoriasis Foundation’s Commit to a Cure Gala in Dallas.
Personal Note
When he’s not at work, Dr. Merola enjoys spending time with family, traveling, cooking, and playing the piano.
Education & Training
Professional Associations & Affiliations
- American Academy of Dermatology
- American College of Rheumatology
- American Dermatological Association
- Association of Program Directors in Internal Medicine
- Association of Professors of Dermatology
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- International Eczema Council
- International Psoriasis Council
- Lupus Foundation of America
- Medical Dermatology Society
- National Psoriasis Foundation
- Noah Worcester Dermatological Society
- Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network
- Rheumatologic Dermatology Society
- Society for Investigative Dermatology
Honors & Awards
- Honoree 2024, National Psoriasis Foundation Gala
- Distinguished Clinician Award 2022, Brigham and Women’s Hospital, Harvard Medical School
- Outstanding Educator in Psoriatic Disease Award 2022, National Psoriasis Foundation Annual Meeting
- Educator of the Year Award 2022, Winter Clinical Dermatology Conference
- Nominee, Senior Faculty Mentorship Award / Pillars of Excellence Award 2022, Mass General Brigham
- Pillars of Excellence Award in Research Leadership 2020, Brigham and Women’s Hospital
- Nominated for Multiple Teaching Awards, Including Bernard Lown Award, Harvard Mentoring Award, and Charles McCabe Award
- Boston Top Doctor for 8 Consecutive Years
Books & Publications
-
Books
-
Teledermatology: Research utilization in Teledermatology: A Comprehensive Overview, Updates in Clinical Dermatology
Shahriari N, Merola JF (2023), Cham, Switzerland, Springer -
Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology (1st ed.)
Garg A, Merola JF, Fitzpatrick L (2022), Springer Publishing -
Drug-induced lupus erythematosus in Clinical Management of Systemic Lupus Erythematosus (2nd ed.)
Merola, JF (1996), Philadelphia, PA, Lippincott-Raven
-
Teledermatology: Research utilization in Teledermatology: A Comprehensive Overview, Updates in Clinical Dermatology
-
Publications
-
Psoriasis
Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF Nature Reviews Disease Primers 2025 Dec 11 -
Novel Therapeutic Targets in the Management of Psoriatic Disease
Childs BA, Merola JF Rheumatic Disease Clinics of North America 2025 Aug 51 447-468 -
Association between lichen planus, psychiatric comorbidities, and psychiatric medication use
Wu A, Rosenberg A, DeBusk L, Mauskar M, Merola JF, Nezafati K JAAD International 2025 Aug 21 34-36 -
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms
Merola JF, Mease PJ, Armstrong AW, Strand V, Lehman T, Varga S, Choi JC, Becker B, Zhong Y, Colombo MJ, Thaçi D, Bili A, Gottlieb AB Dermatology and Therapy 2025 Aug 15 2281-2293 -
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic Disease
Perez-Chada LM, Gondo G, Grant C, Woodbury M, Kucharik AH, Armstrong AW, Eder L, Mease P, Ogdie A, Strand V, Gottlieb AB, Merola JF Journal of Investigative Dermatology 2025 Jul 145 1798-1801.e4 -
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review
Stein Gold L, Eyerich K, Merola JF, Torres J, Coates LC, Allegretti JR Advances in Therapy 2025 Jul 42 3158-3172 -
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial
Kavanaugh A, Coates LC, Mease PJ, Nowak M, Hippeli L, Lehman T, Banerjee S, Merola JF Rheumatology 2025 May 64 2557-2564 -
Psoriatic arthritis: A comprehensive review for the dermatologist–Part II: Screening and management
Elman SA, Perez-Chada LM, Armstrong A, Gottlieb AB, Merola JF Journal of the American Academy of Dermatology 2025 May 92 985-998 -
Psoriatic arthritis: A comprehensive review for the dermatologist part I: Epidemiology, comorbidities, pathogenesis, and diagnosis
Perez-Chada LM, Elman S, Villa-Ruiz C, Armstrong AW, Gottlieb AB, Merola JF Journal of the American Academy of Dermatology 2025 May 92 969-982 -
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System
Schneeweiss MC, Glynn RJ, Wyss R, Anand P, Jin Y, Landon J, Mostaghimi A, Merola JF, Silverberg JI, Rosmarin DM, Sidbury R, Schneeweiss S Journal of Investigative Dermatology 2025 May 145 1070-1080 -
The association between obesity and efficacy of psoriasis therapies: An expert consensus panel
Burshtein J, Armstrong A, Chow M, DeBusk L, Brad Glick G, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van Voorhees A, Lebwohl M Journal of the American Academy of Dermatology 2025 Apr 92 807-815 -
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis
Armstrong AW, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, Yousif J, Grant C, Shields A, Chou P, Callis Duffin K, Gottlieb AB, Merola JF, Perez-Chada L JAMA Dermatology 2025 Apr 161 416-420 -
Development and Validation of Algorithms to Identify Individuals With Cutaneous Lupus From Healthcare Databases
Guo LN, Said JT, Woodbury MJ, Nambudiri VE, Merola JF Journal of Cutaneous Medicine and Surgery 2025 Mar 29 131-136 -
From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments
Childs B, Romanelli S, Merola JF, Gottlieb AB Journal of Clinical and Aesthetic Dermatology 2025 Feb 18 16-22 -
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
Gordon KB, Merola JF, Foley P, Choi O, Chan D, Miller M, Ms YY, Shen YK, Patel HV, Blauvelt A Journal of Drugs in Dermatology 2025 Feb 24 196-202 -
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M Dermatology and Therapy 2025 Feb 15 453-462 -
Early and Sustained Treatment Satisfaction Observed in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab: Results From Second Interim Analysis of the Real-World Psoriasis in Special Areas (PSoSA) Study
Armstrong A, Lonowski S, Fivenson D, Malatestinic W, Murage MJ, Feely Mcdonald M, Sheikhi Mehrabadi A, Merola JF SKIN: Journal of Cutaneous Medicine 2025 Jan 9 24-27 -
Cutaneous lupus matters: Independent and additive quality-of-life burden shown by 2022 WLFGI Survey
Zhang AJ, Ezeh N, Childs B, Farah S, Buie J, Donnelly M, McClamb D, Oberholtzer L, Sharp J, Merola JF Journal of the European Academy of Dermatology and Venereology 2025 -
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414 (Annals of the Rheumatic Diseases (2023) 82(11) (1404–1414), (S0003496724102671), (10.1136/ard-2023-224431))
Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB Annals of the Rheumatic Diseases 2025 -
Correction to: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies (Rheumatology and Therapy, (2024), 11, 5, (1363-1382), 10.1007/s40744-024-00708-8)
Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RB, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC Rheumatology and Therapy 2025 -
Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials
Kearney N, Gorecki P, Acciarri L, Buyze J, Akawung A, Merola JF, Kirby B Dermatology 2025 -
Inter-Rater and Intra-Rater Reliability of the Cutaneous Lupus Activity-Investigator Global Assessment-Revised Instrument
Merola JF, Zhang AJ, Childs BA, Li M, Smith JS, Chong BF, Gottlieb AB, Werth VP, Elman SA, Pérez-Chada LM Journal of Investigative Dermatology 2025 -
Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network
Sheth S, Inestroza K, Merola JF, Weber B, Garshick M Journal of Psoriasis and Psoriatic Arthritis 2025 -
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
Lebwohl M, Deodhar A, Schwartzman S, Salvarani C, Feely McDonald M, Bello N, Grace EL, Inman E, Kronbergs A, Ngantcha M, Rahman P, Papp KA, Merola JF, Gottlieb AB, Blauvelt A Dermatology and Therapy 2025 Jan 15 161-188 -
Eosinophilic Fasciitis and Morphea Share Gene Signatures of Inflammatory Cell Death, Self-DNA Recognition, and Enhanced Jak/Signal Transducer and Activator of Transcription Signaling
Crisler WJ, Rowley R, Oke O, Steuart SJ, Modi MM, Davis DL, Chen C, Gray L, Teague JE, Zhan Q, Merola JF, Vleugels RA, Clark RA, LaChance A Journal of Investigative Dermatology 2025 -
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials
Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, Zhu D, Inman E, Grace E, Holzkaemper T, Rahman P, Marzo-Ortega H, Papp KA, Merola JF, Gottlieb AB, Schwartzman S Arthritis Research and Therapy 2024 Dec 26 -
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U Dermatology and Therapy 2024 Dec 14 3291-3306 -
Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study
Merola JF, Chiou AS, During E, Foley P, Wu J, Ardeleanu M, Ozturk ZE Journal of the American Academy of Dermatology 2024 Dec 91 1199-1201 -
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB BMC Rheumatology 2024 Dec 8 -
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study
Mease PJ, Baraliakos X, Chandran V, Soriano ER, Nash P, Deodhar A, Rampakakis E, Shiff NJ, Chakravarty SD, Shawi M, Merola JF, McInnes IB ACR Open Rheumatology 2024 Dec 6 880-890 -
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting
Zhang AJ, Ball G, Zundell M, Agüero R, Yee D, Shields A, Asare C, Navrazhina K, Liu W, Foolad N, Kwock J, Tejwani P, Hamade H, Jaleel T, Butler D, Silverberg N, Nattkemper L, Siegel DM, Tan J, Kim BS, Larocca C, Shinohara MM, Ehlert A, Latella J, Guttman-Yassky E, Krueger JG, Strand V, Armstrong AW, Merola JF, Perez-Chada L, Gottlieb AB Journal of Drugs in Dermatology 2024 Dec 23 1114-1120 -
Bimekizumab Efficacy and Safety in Patients With Psoriatic Arthritis Who Had Skin and Nail Psoriasis at Baseline: Up to 2-year Results From Two Phase 3 Studies
Thaci D, Asahina A, Boehncke WH, Gottlieb AB, Lebwohl M, Warren RB, Ink B, Bajracharya R, Coarse J, Merola JF SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s435 -
Deucravacitinib in moderate to severe plaque psoriasis: Comorbidities and use of prior and concomitant medication in patients enrolled in the phase 3 poetyk pso-1 and pso-2 trials
Merola JF, Gottlieb AB, Mehta NN, Napoli A, Colombo MJ, Elias M, De Leonardis F, Jou YM, Korman NJ SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s428 -
Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb AB, Strober BE, Merola JF, Mostaghimi A, Farberg AS, Guercio J, Tang M, Thoma C, Lebwohl MG SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s490-s490 -
Ixekizumab Improves Nail, Scalp, and Skin Response and Quality of Life Independent of Baseline Psoriasis Severity: Results From the Psoriasis in Special Areas (PSoSA) Study
Lipner S, Owen C, Korman N, Malatestinic W, McDonald MF, Murage MJ, Mehrabadi AS, Merola JF SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s418 -
Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober BE, Merola JF, Gottlieb AB, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl MG SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s491-s491 -
Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT
Merola JF, Gottlieb AB, Soung J, Hampton P, Pinter A, Gooderham M, Morita A, Kavanagh S, Cross N, Wiegratz S, Paul C SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s432 -
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
Mcgonagle D, Kavanaugh A, Mcinnes IB, Kristensen LE, Merola JF, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C Rheumatology 2024 Nov 63 3115-3123 -
Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober BE, Merola JF, Gottlieb AB, Elewski BE, Guercio J, Tang M, Thoma C, Lebwohl MG SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s489-s489 -
Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola JF, Strober BE, Gottlieb AB, Mostaghimi A, Hawkes JE, Guercio J, Tang M, Thoma C, Lebwohl MG SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s488-s488 -
VEXAS in a patient with hypereosinophilia and Sweet's-like lesions
Longley MJ, Gaffney RG, Smith JS, DeSimone MS, Weinblatt ME, Merola JF JAAD Case Reports 2024 Nov 53 71-74 -
Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 4-Year Analysis of the KEEPsAKE 1 and 2 Trials
Östör A, Glotfelty L, Yue C, Rocc J, Merola JF SKIN: Journal of Cutaneous Medicine 2024 Nov 8 s444 -
Debate at the GRAPPA 2023 Annual Meeting: Should Methotrexate Be the First Systemic Therapy in Psoriatic Disease?
Zhang AJ, Merola JF, Tillett W Journal of Rheumatology 2024 Oct 51 58-60 -
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Gossec L, Coates LC, Gladman DD, Aelion JA, Vasandani J, Pinter A, Merola JF, Kavanaugh A, Reddy J, Wang R, Brunori M, Klyachkin Y, Deignan C, Mease PJ Annals of the Rheumatic Diseases 2024 Oct 83 1480-1488 -
Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact: A Cross-sectional Study
Zundell MP, Perez-Chada L, Tapryal N, Gondo GC, Husni ME, Ball GD, Woodbury MJ, Merola JF, Gottlieb AB Journal of Clinical and Aesthetic Dermatology 2024 Oct 17 19-22 -
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RB, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC Rheumatology and Therapy 2024 Oct 11 1363-1382 -
GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease
Zhang AJ, Perez-Chada LM, Strand V, Armstrong AW, Gottlieb AB, Merola JF Journal of Rheumatology 2024 Oct 51 51-53 -
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting
Ball GD, Yee D, Zhang AJ, Perez-Chada LM, Strand V, Merola JF, Armstrong AW, Gottlieb AB Journal of Rheumatology 2024 Oct 51 16-18 -
Case 22-2024: A Woman with Postpartum Fever, Abdominal Pain, and Skin Ulcers. Reply
Merola JF, Kwan MC, Kroshinsky D The New England journal of medicine 2024 Oct 391 1663 -
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry
Grant C, Perez-Chada LM, Harrison RW, Mclean RR, Dube B, Crabtree MM, Gottlieb AB, Merola JF Clinical and Experimental Dermatology 2024 Sep 49 1016-1023 -
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey
Zundell MP, Ogdie-Beatty AR, Perez-Chada L, Hamade H, Gondo GC, Khan AT, Bell SJ, Levy Z, Merola JF, Gottlieb AB JID Innovations 2024 Sep 4 -
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: Pooled 16-week results from two phase 3 studies
Elaine Husni M, Mease PJ, Merola JF, Tillett W, Goldammer N, Ink B, Coarse J, Lambert J, Taieb V, Gladman DD RMD Open 2024 Sep 10 -
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB Journal of the American Academy of Dermatology 2024 Aug 91 281-289 -
Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB, Lee LW, Merola J, Schwartzman S, Gladman D, Liu C, Koo J, Hawkes JE, Reddy S, Prussick R, Yamauchi P, Lewitt M, Soung J, Weinberg J, Lebwohl M, Glick B, Kircik L, Desai S, Feldman SR, Zaino ML Journal of the American Academy of Dermatology 2024 Aug 91 251.e1-251.e11 -
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Chakravarty SD, Rampakakis E, Shawi M, Schiopu E, Merola JF, McInnes IB, Deodhar A Clinical Rheumatology 2024 Aug 43 2551-2563 -
Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study
Webster DE, Haberman RH, Perez-Chada LM, Tummalacherla M, Tediarjo A, Yadav V, Neto EC, MacDuffie W, DePhillips M, Sieg E, Catron S, Grant C, Francis W, Nguyen M, Yussuff M, Castillo RL, Yan D, Neimann AL, Reddy SM, Ogdie A, Kolivras A, Kellen MR, Mangravite LM, Sieberts SK, Omberg L, Merola JF, Scher JU Journal of Rheumatology 2024 Aug 51 781-789 -
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Soung J, Laquer V, Merola JF, Moore A, Elmaraghy H, Hu C, Piruzeli ML, Pierce E, Garcia Gil E, Jarell AD Dermatology and Therapy 2024 Aug 14 2181-2193 -
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity(Dermatology and Therapy, (2024), 14, (1615-1631), 10.1007/s13555-024-01188-y)
Armstrong AW, Jaleel T, Merola JF, Gottlieb AB, Khattri S, Helt CC, Malatestinic WN, Ross SE, Ngantcha ME, de Vlam K Dermatology and Therapy 2024 Aug 14 2297 -
Prevention of Psoriatic Arthritis: The Need for Prospective Studies
Wu A, Scher JU, Ogdie A, Ritchlin C, Merola JF Dermatologic Clinics 2024 Jul 42 429-438 -
Case 22-2024: A 30-Year-Old Woman with Postpartum Fever, Abdominal Pain, and Skin Ulcers
Merola JF, Cochran RL, Kroshinsky D, Prabhu M, Kwan MC New England Journal of Medicine 2024 Jul 391 260-271 -
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis from the International Psoriasis Council
Choon SE, Van De Kerkhof P, Gudjonsson JE, De La Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thaçi D, Velásquez M, Augustin M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhães R, Capon F, Bachelez H JAMA Dermatology 2024 Jul 160 758-768 -
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Mease PJ, Gladman DD, Merola JF, Nash P, Grieve S, Laliman-Khara V, Willems D, Taieb V, Prickett AR, Coates LC Rheumatology (United Kingdom) 2024 Jul 63 1779-1789 -
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Blauvelt A, Armstrong A, Merola JF, Strober B, de Cuyper D, Peterson L, Davies O, Stark JL, Lebwohl M Journal of the American Academy of Dermatology 2024 Jul 91 72-81 -
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies
Bachelez H, Griffiths CE, Papp KA, Hall S, Merola JF, Feldman SR, Khraishi M, Tan H, Fallon L, Cappelleri JC, Bushmakin AG, Young P Journal of the European Academy of Dermatology and Venereology 2024 Jul 38 e557-e561 -
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Armstrong AW, Jaleel T, Merola JF, Gottlieb AB, Khattri S, Helt CC, Malatestinic WN, Ross SE, Ngantcha ME, de Vlam K Dermatology and Therapy 2024 Jun 14 1615-1631 -
Anifrolumab for the treatment of refractory chilblain lupus erythematosus
Woodbury MJ, Smith KN, Smith JS, Merola JF JAAD Case Reports 2024 Jun 48 69-71 -
Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data
Merola JF, Ertmer B, Liang H, Yue X, Ofori S, Krueger W Journal of the American Academy of Dermatology 2024 May 90 935-944 -
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis A Systematic Review
Pérez-Chada LM, Hopkins ZH, Balak DM, Rashid S, Creadore A, Chu B, Villa C, Woodbury MJ, Armstrong AW, Strand V, Gottlieb AB, Merola JF, Barbieri JS JAMA Dermatology 2024 May 160 550-563 -
Cardiovascular Risk Management in Patients Treated with Janus Kinase Inhibitors
Shah JT, Shah KT, Femia AN, Lo Sicco KI, Merola JF, Weber B, Garshick MS Journal of Cardiovascular Pharmacology 2024 May 83 392-402 -
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF ACR Open Rheumatology 2024 May 6 304-311 -
Expression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies
Klebanov N, Grant C, Smith JS, Perez-Chada LM, Merola JF Journal of Drugs in Dermatology 2024 Apr 23 E118-E119 -
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D Journal of the American Academy of Dermatology 2024 Apr 90 775-782 -
TYK2: an emerging therapeutic target in rheumatic disease
Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R Nature Reviews Rheumatology 2024 Apr 20 232-240 -
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Author Collaboration MB, Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG, Calabrese C, Desai SR, Duffin KC, Feldman SR, Gladman DD, Glick BP, Han G, Harris J, Hawkes JE, Hsu S, Huang MY, Kalb RE, Kircik LH, Koo J, Lewitt GM, Liao WJ, Liu C, Merola JF, Prussick RB, Reddy SM, Schwartzman S, Smith JN, Soung J, Van Voorhees AS, Wallace EB, Weinberg JM, Lee LW, Yamauchi PS Journal of the American Academy of Dermatology 2024 Apr 90 727-730 -
Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial
Gottlieb AB, Armstrong AW, Merola JF, Napoli A, Nowak M, Banerjee S, Lehman T, Mease PJ SKIN: Journal of Cutaneous Medicine 2024 Mar 8 S383 -
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA Journal of the American Academy of Dermatology 2024 Mar 90 485-493 -
Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
Zhang A, Gaffney RG, Merola JF JAAD Case Reports 2024 Mar 45 110-112 -
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies
Merola JF, Chakravarty SD, Choi O, Chan D, Gottlieb AB Journal of the American Academy of Dermatology 2024 Feb 90 349-357 -
Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation
Author Collaboration NP, Hackley M, Thampy D, Waseh S, Feldman SR, Blauvelt A, Weinberg JM, Schwartzman S, Liao W, Prussick R, Cohen JM, Hsu S, Gladman DD, Reddy S, Merola J, Calabrese C, Lebwohl M, Kindred C, Miller L, Kircik L, Liu C, Lewitt GM, Lee LW, Desai S, Van Voorhees A, Glick BP, Soung J Journal of the American Academy of Dermatology 2024 Feb 90 408-410 -
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola JF, Gordon K, Shahriari M, Korman NJ, Chovatiya R, Kalb R, Lebwohl M Dermatology and Therapy 2024 Feb 14 323-339 -
A New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers
Zundell MP, Merola JF, Gottlieb AB Journal of Drugs in Dermatology 2024 Feb 23 105-109 -
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Coates LC, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Orbai AM, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Merola JF RMD Open 2024 Feb 10 -
Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab
Gaffney RG, Merola JF JAAD Case Reports 2024 Feb 44 71-73 -
Expert consensus achieved on a working core outcome set for cutaneous lupus erythematosus research in survey following the 5th International Conference on Cutaneous Lupus Erythematosus (ICCLE)
Zhang AJ, Perez-Chada LM, Werth VP, Merola JF Lupus Science and Medicine 2024 Feb 11 -
A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
Woodbury MJ, Grant C, Perez-Chada L, Lachance AH, Merola JF Journal of Drugs in Dermatology 2024 Feb 23 e60-e63 -
Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?
Merola JF, Nyberg F, Franchimont N, Barbey C, Werth VP Frontiers in Medicine 2024 11 -
Exploring the Clinical Presentation, Course, and Burden of Disease in Generalized Pustular Psoriasis [Podcast]
Merola JF, Amin AZ Clinical, Cosmetic and Investigational Dermatology 2024 17 539-545 -
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE Journal of Dermatological Treatment 2024 35 -
Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort study
Schneeweiss MC, Wyss R, Schneeweiss S, Anand P, Jin Y, Dicesare E, Glynn RJ, Merola JF Journal of the American Academy of Dermatology 2024 Jan 90 134-137 -
Successful Treatment of Keloids and Hypertrophic Scars With Systemic and Intralesional Dupilumab
Min MS, Mazori DR, Lee MS, Merola JF, AnnVleugels R, Cobos G, LaChance AH Journal of Drugs in Dermatology 2023 Dec 22 1220-1222 -
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF Rheumatology and Therapy 2023 Dec 10 1479-1501 -
International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting
Lee K, Woodbury MJ, Zundell MP, Agüero R, Yousif J, Williams SC, Rosmarin D, Silverberg N, Thiboutot D, Larocca C, Shinohara MM, Mostaghimi A, Ständer S, Martorell A, Jaleel T, Torbeck RL, Siegel DM, Perez-Chada L, Strand V, Armstrong AW, Merola JF, Gottlieb AB Journal of Drugs in Dermatology 2023 Dec 22 1153-1159 -
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
Merola JF, Chiou AS, During E, Costanzo A, Foley P, Alfalasi A, Gogate S, Pinter A, Dodiuk-Gad R, Simon D, Tauber M, Weller R, Pereyra-Rodriguez JJ, Ardeleanu M, Wu J, Ozturk ZE British Journal of Dermatology 2023 Dec 189 685-694 -
Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective
Woodbury MJ, Smith JS, Merola JF American Journal of Clinical Dermatology 2023 Nov 24 859-864 -
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB Annals of the Rheumatic Diseases 2023 Nov 82 1404-1414 -
Proceedings of the GRAPPA 2022 Executive Retreat
Ng BC, Jadon D, Adebajo A, Ayan G, Duffin KC, Chandran V, Coates LC, D’Agostino MA, de Vlam K, Deodhar A, Eder L, Garg A, Gladman DD, Goel N, Gottlieb AB, Husni ME, Katz A, Kavanaugh A, Lubrano E, Mease PJ, Merola JF, Nash P, Ogdie A, Pennington SR, Perez-Chada LM, Proft F, Rosen CF, Savage L, Goldenstein-Schainberg C, Siebert S, Soriano ER, Steinkoenig I, Tillett W, Armstrong AW, FitzGerald O Journal of Rheumatology 2023 Nov 50 71-77 -
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
Orbai AM, Chakravarty SD, You Y, Shawi M, Yang YW, Merola JF Dermatology and Therapy 2023 Nov 13 2859-2868 -
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database
Merola JF, Patil D, Egana A, Steffens A, Webb NS, Gottlieb AB Dermatology and Therapy 2023 Nov 13 2635-2648 -
Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 3-Year Analysis of the KEEPsAKE 1 and 2 Trials
Östör A, Chen M, Padilla B, Yue C, Photowala H, Rocco J, Merola JF SKIN: Journal of Cutaneous Medicine 2023 Nov 7 s249-s249 -
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group
Leung YY, Tillett DW, de Wit M, Orbai CA, Coates LC, FitzGerald O, Helliwell PS, Strand V, Mease PJ, Goel N, Christensen R, Merola JF, Lindsay CA, Ogdie BA, Gossec L, Gladman DD Journal of Rheumatology 2023 Nov 50 53-57 -
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting
Zundell MP, Woodbury MJ, Lee K, Perez-Chada LM, Armstrong AW, Strand V, Merola JF, Gottlieb AB Journal of Rheumatology 2023 Nov 50 47-50 -
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?
Agüero R, Woodbury MJ, Lee K, Johnsson HJ, Merola JF, Armstrong AW Journal of Rheumatology 2023 Nov 50 11-13 -
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
Merola JF, Butler DC, Mark T, Schneider S, Kim Y, Abuabara K JAMA Dermatology 2023 Oct 159 1119-1123 -
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Kirkham BW, Egeberg A, Behrens F, Pinter A, Merola JF, Holzkämper T, Gallo G, Ng KJ, Bolce R, Schuster C, Nash P, Puig L Rheumatology and Therapy 2023 Oct 10 1127-1146 -
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings
Grant C, Perez-Chada L, Haberman RH, Webster D, FitzGerald O, Ritchlin C, Chandran V, Rosen CF, Weber B, Garshick M, Eder L, Reddy SM, Ogdie A, Scher JU, Merola JF Journal of Psoriasis and Psoriatic Arthritis 2023 Oct 8 179-183 -
A case of paradoxical eosinophilic fasciitis in a patient on benralizumab
Woodbury MJ, Gaffney RG, Merola JF JAAD Case Reports 2023 Oct 40 45-46 -
Discoid lupus erythematosus of the nail treated with thalidomide
Harp T, Woodbury MJ, Merola JF JAAD Case Reports 2023 Oct 40 106-108 -
Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA Survey
Song K, Webb L, Eder L, FitzGerald O, Goel N, Helliwell PS, Katz A, Merola JF, Rosen CF, Coates LC, Poddubnyy D Journal of Rheumatology 2023 Sep 50 1439-14445 -
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
Gottlieb AB, Burge R, Malatestinic WN, Zhu B, Zhao Y, McCormack J, Kimel M, Merola JF Dermatology and Therapy 2023 Aug 13 1831-1846 -
Ruxolitinib cream for the treatment of cutaneous sarcoidosis
Smith JS, Woodbury MJ, Merola JF JAAD Case Reports 2023 Aug 38 111-112 -
Upper portion of the eyelid blepharoplasty for a patient with recalcitrant Morbihan disease
Woodbury MJ, Chen SX, Stagner AM, Lee NG, Merola JF JAAD Case Reports 2023 Aug 38 102-104 -
Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US study
Schoder K, Zhu Y, Schneeweiss S, Merola JF, Savage TJ, Gibbs LR, Schneeweiss MC Journal of the American Academy of Dermatology 2023 Jul 89 178-181 -
Venous Thromboembolism in Patients with Bullous Pemphigoid
Schneeweiss MC, Merola JF, Wyss R, Silverberg JI, Mostaghimi A JAMA Dermatology 2023 Jul 159 750-756 -
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure
Lebwohl MG, Merola JF, Rowland K, Miller M, Yang YW, Yu J, You Y, Chan D, Thaçi D, Langley RG British Journal of Dermatology 2023 Jul 189 42-52 -
Questions about the BE COMPLETE trial – Authors' reply
Merola JF, McInnes IB The Lancet 2023 Jun 401 1927 -
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey
Merola JF, Ogdie A, Gottlieb AB, Stein Gold L, Flower A, Jardon S, Klyachkin Y, Lebwohl M Dermatology and Therapy 2023 Jun 13 1329-1346 -
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
Zakria D, Brownstone N, Armstrong AW, Boh EE, Koo JY, Merola JE, Pariser D, Lebwohl M Journal of Drugs in Dermatology 2023 Jun 22 588-593 -
Questions about the BE OPTIMAL trial – Authors' reply
McInnes IB, Merola JF The Lancet 2023 Jun 401 1928 -
Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: Review and interim guidance from the Medical Dermatology Society
Kumar AM, Chen ST, Merola JF, Mostaghimi A, Zhou XA, Fett N, Smith GP, Saavedra AP, Noe MH, Rosenbach M Journal of the American Academy of Dermatology 2023 Mar 88 623-631 -
Risk of Infection in Children with Psoriasis Receiving Treatment with Ustekinumab, Etanercept, or Methotrexate before and after Labeling Expansion
Schneeweiss MC, Savage TJ, Wyss R, Jin Y, Schoder K, Merola JF, Sidbury R, Oduol T, Schneeweiss S, Glynn RJ JAMA Dermatology 2023 Mar 159 289-298 -
A national survey comparing practice patterns and residency training satisfaction for categorical dermatology versus combined internal medicine and dermatology trained physicians
Han J, Ronkainen SD, Jacobsen A, Bohjanen KA, Merola JF, Colavincenzo ML, DeWitt CA, Fett NM, Haemel A, Rosenbach M, Werth VP, Lunos S, Goldfarb N Dermatology online journal 2023 Mar 29 -
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Haaland D, Chen L, Duan Y, Liu J, Lippe R, Wung P Rheumatology and Therapy 2023 Feb 10 275-292 -
Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review
Prinz JC, Choon SE, Griffiths CE, Merola JF, Morita A, Ashcroft DM, Viguier M Journal of the European Academy of Dermatology and Venereology 2023 Feb 37 256-273 -
Intravenous immunoglobulin–refractory necrobiotic xanthogranuloma successfully treated with tofacitinib 2% cream
Shahriari N, Mazori DR, Merola JF JAAD Case Reports 2023 Feb 32 41-43 -
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Duffin KC, Mazzuoccolo LD, Cura MJ, Esposito M, Fernandez AP, Gisondi P, Giunta A, Hillary T, Piaserico S, Solomon JA, Merola JF Journal of Rheumatology 2023 Jan 50 131-143 -
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
Egeberg A, Merola JF, Schäkel K, Puig L, Mahar PD, Wang IY, Pavo I, Schuster C, Griffiths CE Frontiers in Medicine 2023 Jan 9 -
The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: A Danish population-based cohort study
Petersen MB, Hansen RL, Egeberg A, Jørgensen TS, Merola JF, Coates LC, Kristensen LE Rheumatology Advances in Practice 2023 7 -
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ The Lancet 2023 Jan 401 25-37 -
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC The Lancet 2023 Jan 401 38-48 -
Presentation, management, and outcomes of cauda equina syndrome up to one year after surgery, using clinician and participant reporting: A multi-centre prospective cohort study
Author Collaboration UC, Author Collaboration BN, Woodfield J, Hoeritzauer I, Jamjoom AA, Jung J, Lammy S, Pronin S, Hannan CJ, Watts A, Hughes L, Moon RD, Darwish S, Roy H, Copley PC, Poon MT, Thorpe P, Srikandarajah N, Grahovac G, Demetriades AK, Eames N, Sell PJ, Statham PF, Abdelsadg M, Abulaila MM, Ahmed U, Ajmi Q, Al-Mahfoudh R, Ali C, Amarouche M, Andalib A, Arora M, Arora M, Awan M, Baig Mirza A, Bateman A, Bennett I, Bhatti I, Bodkin P, Bommireddy L, Bonanos G, Borg A, Boukas A, Bourne J, Brennan R, Brown J, Brown K, Burton O, Busby C, Chiverton N, Clark S, Merola J The Lancet Regional Health - Europe 2023 Jan 24 -
Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures
Skougaard M, Stisen ZR, Jørgensen TS, Egeberg A, Hansen RL, Perez-Chada LM, Mogensen M, Merola JF, Gerwien JG, Kristensen LE Scandinavian Journal of Rheumatology 2023 52 259-267 -
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders
Author Collaboration ID, Author Collaboration AA, Perez-Chada L, Taliercio VL, Gottlieb AB, Van Beek M, Duffin KC, Reeder M, Merola JF, Swerlick RA Journal of the American Academy of Dermatology 2023 Jan 88 86-93 -
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes(Front. Med., (2023), 9, (1092688), 10.3389/fmed.2022.1092688)
Egeberg A, Merola JF, Schäkel K, Puig L, Mahar PD, Wang IY, Pavo I, Schuster C, Griffiths CE Frontiers in Medicine 2023 10 -
Sleep Problems in Patients With Psoriatic Arthritis: A Systematic Literature Review and Metaanalysis
Grant C, Woodbury M, Skougaard M, Boldsen JK, Ogdie A, Klerman EB, Merola JF, Perez-Chada LM Journal of Rheumatology 2023 50 1594-1609 -
Extension-elicited blanching of the dorsal phalanges in systemic sclerosis: A case series
Schunkert EM, Smith JS, Elman SA, Merola JF JAAD Case Reports 2022 Dec 30 87-90 -
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, Gossec L, Assudani D, Bajracharya R, Coarse J, Ink B, Ritchlin CT Arthritis and Rheumatology 2022 Dec 74 1959-1970 -
Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis
Lin CP, Merola JF, Wallace EB Current Opinion in Pharmacology 2022 Dec 67 -
Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation
Balak DM, Perez-Chada LM, Guo LN, Mita C, Armstrong AW, Bell SJ, Gondo GC, Liao W, Merola JF Journal of the European Academy of Dermatology and Venereology 2022 Dec 36 2291-2300 -
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): Protocol of a randomised, double-blind, placebo controlled multicentre trial
Haberman RH, Macfarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU BMJ Open 2022 Dec 12 -
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
Mease P, van der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola JF, Pricop L, James DA, Zhu X, Ligozio G Arthritis Research and Therapy 2022 Dec 24 -
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials*
Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sallé D, Girolomoni G, Papp K, de Bruin-Weller M, Thyssen JP, Zachariae R, Olsen CK, Wollenberg A British Journal of Dermatology 2022 Dec 187 888-899 -
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, McLean RR, Malley W, Spitzer RL, Kavanaugh A, Merola JF Drugs - Real World Outcomes 2022 Dec 9 617-628 -
Perspectives on Nonmedical Switching and the COVID-19 Pandemic: A Narrative Review
Merola JF, Armstrong AW, Phares S, Hass S, Yi E, Patil D, Lebwohl M American Journal of Managed Care 2022 Nov 28 E417-E425 -
Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist
Woodbury MJ, Cohen JM, Merola JF, Perez-Chada LM Journal of the American Academy of Dermatology 2022 Nov 87 1075-1080 -
Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis
Jin Y, Lee H, Lee MP, Landon JE, Merola JF, Desai RJ, Kim SC Arthritis Care and Research 2022 Nov 74 1792-1805 -
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study*
Schneeweiss MC, Kirchgesner J, Wyss R, Jin Y, York C, Merola JF, Mostaghimi A, Silverberg JI, Schneeweiss S, Glynn RJ British Journal of Dermatology 2022 Nov 187 692-703 -
Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients with Atopic Dermatitis Treated with Dupilumab: A US Multidatabase Cohort Study
Schneeweiss MC, Wyss R, Chin K, Merola JF, Silverberg JI, Mostaghimi A, Schneeweiss S Dermatitis 2022 Nov 33 S73-S82 -
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC Rheumatology and Therapy 2022 Oct 9 1451-1464 -
Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
Merola JF, Kavanaugh A, Lebwohl MG, Gniadecki R, Wu JJ Dermatology and Therapy 2022 Oct 12 2201-2216 -
Cutaneous lupus erythematosus disease assessment: Highlighting CLE outcome measures
Gaffney RG, Werth VP, Merola JF Frontiers in Medicine 2022 Oct 9 -
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysis
Wu JJ, Hong Ch, Merola JF, Gruben D, Güler E, Feeney C, Bhambri A, Myers DE, DiBonaventura M Annals of Allergy, Asthma and Immunology 2022 Sep 129 354-359.e5 -
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
Coates LC, Smolen JS, Mease PJ, Husni ME, Merola JF, Lespessailles E, Kishimoto M, Macpherson L, Bradley AJ, Bolce R, Helliwell PS RMD Open 2022 Sep 8 -
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A, Orbai AM, Scher JU, Kavanaugh A, Kianifard F, Rollins C, Calheiros R, Chambenoit O Journal of Rheumatology 2022 Aug 49 894-902 -
International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
Zagona-Prizio C, Yousif J, Grant C, Mehta M, Rosmarin D, Silverberg N, Tan JK, Larocca C, Shinohara MM, Mostaghimi A, Kim B, Gulliver S, Gulliver W, Siegel DM, Perez-Chada L, Merola JF, Gottlieb AB, Armstrong AW Journal of Drugs in Dermatology 2022 Aug 21 867-874 -
Treatment of immune checkpoint inhibitor–mediated psoriasis: A systematic review
Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR Journal of the American Academy of Dermatology 2022 Aug 87 399-400 -
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
Gondo G, Mosca M, Hong J, Maverakis E, Merola JF, Armstrong AW, Bhutani T, Bell SJ, Liao W Dermatology and Therapy 2022 Aug 12 1885-1895 -
Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial
Mease PJ, Gladman DD, Merola JF, Deodhar A, Ogdie A, Collier DH, Liu L, Kavanaugh A Journal of Rheumatology 2022 Aug 49 885-893 -
Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review
Balak DM, Perez-Chada LM, Guo LN, Mita C, Armstrong AW, Bell SJ, Gondo GC, Liao W, Merola JF Journal of Investigative Dermatology 2022 Jul 142 2026-2029.e4 -
Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement
Said JT, Elman SA, Tawa M, Fisher DC, Merola JF, Kupper TS Dermatologic Therapy 2022 Jul 35 -
Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
Blauvelt A, Rich P, Sofen H, Lambert J, Merola JF, Lebwohl M, Hippeli L, Kisa RM, Banerjee S, Kimball AB SKIN: Journal of Cutaneous Medicine 2022 Jul 6 s41 -
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Elmariah SB, Smith JS, Merola JF American Journal of Clinical Dermatology 2022 Jul 23 427-431 -
Bimekizumab Safety in Patients with Moderate to Severe Plaque Psoriasis: Pooled Results from Phase 2 and Phase 3 Randomized Clinical Trials
Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D JAMA Dermatology 2022 Jul 158 735-744 -
Emerging Therapies in Cutaneous Lupus Erythematosus
Sprow G, Dan J, Merola JF, Werth VP Frontiers in Medicine 2022 Jul 9 -
2021 GRAPPA Meet the Experts Session: A Summary of Presentations
Armstrong AW, Reddy RM, FitzGerald O, Duffin KC, Helliwell PS, Mease PJ, Kavanaugh A, Merola JF, Tillet W, Wit Md The Journal of rheumatology 2022 Jun 49 32-36 -
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF Journal of the European Academy of Dermatology and Venereology 2022 Jun 36 797-806 -
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN Rheumatology and Therapy 2022 Jun 9 935-955 -
Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting
Yousif JE, Merola JF, Perez-Chada LM, Zagona-Prizio C, Armstrong AW, Ogdie A, Shin S, Gottlieb AB The Journal of rheumatology 2022 Jun 49 40-43 -
Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists
Gottlieb AB, Wells AF, Merola JF Clinical Rheumatology 2022 May 41 1271-1283 -
Lack of association between tumor necrosis factor-α inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study
Min MS, Kassamali B, Mazori DR, Gizelis O, Schaefer M, Ho A, Merola JF, Cobos G, LaChance AH, Vleugels RA Journal of the American Academy of Dermatology 2022 May 86 1180-1182 -
Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1
Kristensen LE, Soliman AM, Papp K, Merola JF, Barcomb L, Wang Z, Eldred A, Behrens F Journal of the European Academy of Dermatology and Venereology 2022 May 36 e389-e392 -
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting
Kohn AH, Alavi A, Armstrong AW, Babalola F, Garg A, Gottlieb AB, Grilli L, Jemec GB, Latella J, Marcus K, Merola JF, Ortega-Loayza AG, Siegel DM, Strand V, Tan JK, Perez-Chada LM Dermatology 2022 May 238 430-437 -
Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial
Ryan C, Guenther L, Foley P, Weisman J, Burge RT, Gallo G, See K, McKean-Matthews M, Bertram CC, Merola JF Journal of the European Academy of Dermatology and Venereology 2022 Apr 36 e277-e279 -
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC Dermatology and Therapy 2022 Apr 12 911-920 -
Tofacitinib for refractory chilblain lupus erythematosus
Elman SA, Mazori DR, Merola JF International Journal of Dermatology 2022 Apr 61 e156-e157 -
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States
Merola JF, Tian H, Patil D, Richardson C, Scott A, Chen YH, Kim N, Hur P, Armstrong AW Journal of the American Academy of Dermatology 2022 Apr 86 748-757 -
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
Armstrong AW, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola JF, Langley RG, Ståhle M, Lebwohl M, Netea MG, Nunez Gomez N, Warren RB Dermatology and Therapy 2022 Mar 12 787-800 -
A novel variant in the GNAS complex locus causes Albright hereditary osteodystrophy with pseudopseudohypoparathyroidism
Smith JS, Aldeeri AA, Elman SA, Krier JB, Merola JF JAAD Case Reports 2022 Mar 21 103-105 -
Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis
Gondo G, Hadeler E, Brownstone N, Maverakis E, Merola JF, Armstrong AW, Bhutani T, Bell SJ, Liao W Dermatology and Therapy 2022 Mar 12 753-760 -
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: Pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Schiopu E, Chakravarty SD, Kollmeier AP, Xu XL, Shawi M, Jiang Y, Sheng S, Wang Y, Xu S, Merola JF, McInnes IB, Deodhar A RMD Open 2022 Mar 8 -
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB Dermatology and Therapy 2022 Feb 12 495-510 -
Coronary microvascular dysfunction in patients with psoriasis
Weber B, Perez-Chada LM, Divakaran S, Brown JM, Taqueti V, Dorbala S, Blankstein R, Liao K, Merola JF, Di Carli M Journal of Nuclear Cardiology 2022 Feb 29 37-42 -
Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers
Min MS, Alsarheed A, Kassamali B, Mazori DR, Schaefer M, Merola JF, Cobos G, LaChance AH, Vleugels RA Journal of the American Academy of Dermatology 2022 Feb 86 423-425 -
Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study
Cohen JM, Kridin K, Perez-Chada LM, Merola JF, Cohen AD International Journal of Dermatology 2022 Jan 61 84-88 -
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G Journal of Dermatological Treatment 2022 33 2614-2620 -
A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis
Gottlieb AB, Merola JF Journal of Dermatological Treatment 2022 33 1907-1915 -
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
Feldman SR, Merola JF, Pariser DM, Zhang J, Zhao Y, Mendelsohn AM, Gottlieb AB Journal of Dermatological Treatment 2022 33 1670-1675 -
Evaluation of the Integumentary and Musculokeletal Systems: An Approach to the Interdisciplinary Examination for Overlap Diseases
Patel-Cohen M, Garg A, Said JT, Merola JF 2022 Jan 1-10 -
Does biologic therapy impact the development of PsA among patients with psoriasis?
Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, Chen Y, Xie S, Choi H, Zhang Y, Scher JU, Ritchlin CT, Gelfand JM, Ogdie A Annals of the Rheumatic Diseases 2022 Jan 81 80-86 -
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF Dermatology and Therapy 2022 Jan 12 97-119 -
Interdisciplinary Approaches to Overlap Disorders in Dermatology and Rheumatology
Garg A, Merola JF, Fitzpatrick L 2022 Jan -
Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
de Bruin-Weller M, Merola JF, Hong Ch, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB Dermatology and Therapy 2021 Dec 11 2123-2131 -
Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey
Gondo GC, Merola JF, Bell SJ, Blauvelt A British Journal of Dermatology 2021 Dec 185 1264-1265 -
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need
Guo LN, Perez-Chada LM, Borucki R, Nambudiri VE, Werth VP, Merola JF Lupus Science and Medicine 2021 Dec 8 -
Does psoriasis treatment affect PsA development?
Merola JF, Ogdie A Nature Reviews Rheumatology 2021 Dec 17 708-709 -
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CE, Bao W, Pellet P, Pricop L, McInnes IB British Journal of Dermatology 2021 Dec 185 1124-1134 -
Disseminated varicella-zoster virus infections following messenger RNA–based COVID-19 vaccination
Said JT, Virgen CA, Lian CG, Cutler CS, Merola JF, LeBoeuf NR JAAD Case Reports 2021 Nov 17 126-129 -
A case of paradoxical fibrosis and development of morphea in a patient on dupilumab
Kassamali B, Elman SA, Sheets AR, LaChance AH, Merola JF JAAD Case Reports 2021 Nov 17 7-8 -
OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud’s Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness
Kassamali B, Desai S, Min MS, Mazori DR, Villa-Ruiz C, Kus KJ, Cobos GA, Merola J, LaChance A, Vleugels RA Journal of Drugs in Dermatology 2021 Nov 20 1257-1258 -
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders
Weber BN, Stevens E, Perez-Chada LM, Brown JM, Divakaran S, Bay C, Bibbo C, Hainer J, Dorbala S, Blankstein R, Taqueti VR, Merola JF, Massarotti E, Costenbader K, Liao K, Di Carli MF JACC: Cardiovascular Imaging 2021 Nov 14 2212-2220 -
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics
Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS Current atherosclerosis reports 2021 Nov 23 -
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials
Warren RB, Gottlieb AB, Merola JF, Garcia L, Cioffi C, Peterson L, Pelligra C, Ciaravino V Dermatology and Therapy 2021 Oct 11 1551-1569 -
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, Haaland D, Chen L, Duan Y, Zueger P, Liu J, Lippe R, Pangan AL, Behrens F RMD Open 2021 Oct 7 -
Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020
Merola JF, Dennis N, Chakravarty SD, Villacorta R, Mesana L, Lin I, Wang Y, Shawi M, Pacou M, Baker T, Peterson S Clinical Rheumatology 2021 Oct 40 4061-4070 -
Measuring fatigue: a meta-review
Machado MO, Kang NY, Tai F, Sambhi RD, Berk M, Carvalho AF, Chada LP, Merola JF, Piguet V, Alavi A International Journal of Dermatology 2021 Sep 60 1053-1069 -
Itch as major mediator of effect of tofacitinib on health‐related quality of life in psoriatic arthritis: A mediation analysis
Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G Journal of Clinical Medicine 2021 Sep 10 -
Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis
Scher JU, Ogdie A, Merola JF, Ritchlin C Arthritis and Rheumatology 2021 Sep 73 1574-1578 -
Hidradenitis suppurativa and sleep disorders: a population-based study
Cohen JM, Kridin K, Perez-Chada LM, Merola JF, Cohen AD Journal of the European Academy of Dermatology and Venereology 2021 Aug 35 e520-e522 -
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis
Schneeweiss MC, Perez-Chada L, Merola JF Journal of the American Academy of Dermatology 2021 Aug 85 321-329 -
The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies
Min MS, Kassamali B, Mazori DR, Vleugels RA, Merola JF, Cobos G, LaChance AH Journal of the American Academy of Dermatology 2021 Aug 85 517-519 -
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis
Jin Y, Chen SK, Lee H, Landon JE, Merola JF, Kim SC Journal of managed care & specialty pharmacy 2021 Aug 27 1106-1117 -
Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis
Gottlieb AB, Bakewell C, Merola JF Dermatology and Therapy 2021 Aug 11 1199-1216 -
Validation of claims-based algorithms to identify patients with psoriasis
Lee H, He M, Cho SK, Bessette L, Tong AY, Merola JF, Wegrzyn LR, Kilpatrick RD, Kim SC Pharmacoepidemiology and Drug Safety 2021 Jul 30 868-874 -
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
Merola JF, Bagel J, Almgren P, Røpke MA, Lophaven KW, Vest NS, Grewal P Journal of the American Academy of Dermatology 2021 Jul 85 71-78 -
Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand
Armstrong A, Lebwohl M, Merola JF, Koons S, Fried R, Hawkes J, Koo J, Langley R, Martin G, Reddy S, Schwartzman S, Siegel E, Van Voorhees A, Wallace E, Weinberg J, Howard L, Bell S Journal of Psoriasis and Psoriatic Arthritis 2021 Jul 6 126-127 -
Incidence of Venous Thromboembolism in Patients with Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases
Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, Mostaghimi A, Silverberg JI, Schneeweiss S JAMA Dermatology 2021 Jul 157 805-816 -
Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus
Mazori DR, Min MS, Kassamali B, Brichta L, Merola JF, Vleugels RA, Lachance AH JAMA Dermatology 2021 Jul 157 880-882 -
Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies
Klebanov N, Perez-Chada LM, Gupta S, Gottlieb AB, Merola JF Journal of the American Academy of Dermatology 2021 Jul 85 249-252 -
Pustular Psoriasis and Associated Musculoskeletal Disorders
Duffin KC, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola JF, Chau J, Kishimoto M, Furer V, Helliwell PS The Journal of rheumatology. Supplement 2021 Jun 97 34-38 -
Pseudovasculitis: an etiology not to miss
Elman SA, Mazori DR, Merola JF Clinical Rheumatology 2021 Jun 40 2505-2506 -
Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients
Kassamali B, Kus KJ, Min MS, Villa-Ruiz C, Cobos GA, Merola JF, Vleugels RA, Mazori DR, LaChance AH JAAD International 2021 Jun 3 111-114 -
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting
Perez-Chada LM, Kohn A, Gottlieb AB, Armstrong AW, Eder L, Mease PJ, Ogdie A, Strand V, Merola JF The Journal of rheumatology. Supplement 2021 Jun 97 10-16 -
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting
Mease PJ, Calabrese LH, Duffin KC, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF The Journal of rheumatology. Supplement 2021 Jun 97 24-29 -
Seroconversion of severe acute respiratory syndrome coronavirus 2–infected patients on immunosuppression: A retrospective analysis
Smith JS, Said JT, Elman SA, Smith CE, Merola JF Journal of the American Academy of Dermatology 2021 May 84 1409-1412 -
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT Journal of the American Academy of Dermatology 2021 May 84 1254-1268 -
Correction to: Pseudovasculitis: an etiology not to miss (Clinical Rheumatology, (2021), 10.1007/s10067-020-05548-9)
Elman SA, Mazori DR, Merola JF Clinical Rheumatology 2021 May 40 2119 -
Trial of upadacitinib and adalimumab for psoriatic arthritis
McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, PachecoTena C, Wang X, Chen L, Zueger P, Liu J, Pangan AL, Behrens F New England Journal of Medicine 2021 Apr 384 1227-1239 -
Step Therapy Re-Imagined
LaChance A, Merola JF Journal of Psoriasis and Psoriatic Arthritis 2021 Apr 6 88-89 -
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L, Mease P, Reddy S, Ogdie A, Merola JF, Scher JU Nature Reviews Rheumatology 2021 Apr 17 238-243 -
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Coates LC, Merola JF, Mease PJ, Ogdie A, Gladman DD, Strand V, Van Mens LJ, Liu L, Yen PK, Collier DH, Kricorian G, Chung JB, Helliwell PS Rheumatology (United Kingdom) 2021 Mar 60 1137-1147 -
De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis
Bui AT, Singer S, Hirner J, Cunningham-Bussel AC, Larocca C, Merola JF, Lian CG, LeBoeuf NR Journal of the American Academy of Dermatology 2021 Mar 84 864-869 -
Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)
Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW Dermatology 2021 Mar 237 151-157 -
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
Merola JF, Wang W, Wager CG, Hamann S, Zhang X, Thai A, Roberts C, Lam C, Musselli C, Marsh G, Rabah D, Barbey C, Franchimont N, Reynolds TL Lupus Science and Medicine 2021 Mar 8 -
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study
Schneeweiss MC, Kim SC, Wyss R, Schneeweiss S, Merola JF Journal of the American Academy of Dermatology 2021 Feb 84 300-311 -
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb AB, Merola JF, Cirulli J, Williams CC, Linowski GJ, Paris M, Litman HJ, Guo N, Emeanuru K, McLean RR, Cronin A, Strober B Dermatology and Therapy 2021 Feb 11 253-263 -
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Merola JF, Sidbury R, Wollenberg A, Chen Z, Zhang A, Shumel B, Rossi AB Journal of the American Academy of Dermatology 2021 Feb 84 495-497 -
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M The Lancet 2021 Feb 397 487-498 -
Severe recalcitrant otic lichen planus treated with mycophenolate mofetil
Guo LN, Shin JJ, Schulte S, Merola JF JAAD Case Reports 2021 Feb 8 1-3 -
Development of a Set of Lupus-Specific, Ambulatory Care–Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study
Feldman CH, Speyer C, Ashby R, L. Bermas B, Bhattacharyya S, Chakravarty E, Everett B, Ferucci E, Hersh AO, Marty FM, Merola JF, Ramsey-Goldman R, Rovin BH, Son MB, Tarter L, Waikar S, Yazdany J, Weissman JS, Costenbader KH Arthritis Care and Research 2021 Jan 73 146-157 -
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: An observational cohort study
Skougaard M, Jørgensen TS, Jensen MJ, Ballegaard C, Guldberg-Møller J, Egeberg A, Christensen R, Benzin P, Stisen ZR, Merola JF, Coates LC, Strand V, Mease P, Kristensen LE Rheumatology Advances in Practice 2021 5 -
Axial psoriatic arthritis: An update for dermatologists
Gottlieb AB, Merola JF Journal of the American Academy of Dermatology 2021 Jan 84 92-101 -
Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa
Schneeweiss MC, Merola JF, Schneeweiss S, Wyss R, Rosmarin D Journal of the European Academy of Dermatology and Venereology 2021 Jan 35 195-202 -
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
Strand V, Mease PJ, Hernandez EJ, Stolshek BS, Liu LX, Collier DH, Kricorian G, Merola JF RMD Open 2021 Jan 7 -
Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: A clinical review
Tan AJ, Streicher JL, Merola JF, Noe MH Dermatology online journal 2021 27 -
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT Journal of the American Academy of Dermatology 2020 Dec 83 1704-1716 -
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies
Merola JF, Papp KA, Nash P, Gratacós J, Boehncke WH, Thaçi D, Graham D, Hsu MA, Wang C, Wu J, Young P Journal of the European Academy of Dermatology and Venereology 2020 Dec 34 2809-2820 -
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CE Journal of the American Academy of Dermatology 2020 Nov 83 1367-1374 -
Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN
Bell S, Merola JF, Webster DE, Pennington SR, Liao W, Ogdie A, FitzGerald O, Ritchlin C, Scher JU Current Rheumatology Reports 2020 Nov 22 -
Report from the International Dermatology Outcome Measures Initiative
Perez-Chada LM, Merola JF, Armstrong AW, Garg A, Latella J, Gottlieb AB Journal of Investigative Dermatology Symposium Proceedings 2020 Nov 20 S80-S83 -
Psoriatic arthritis for dermatologists
Gottlieb A, Merola JF Journal of Dermatological Treatment 2020 Oct 31 662-679 -
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
Zahedi Niaki O, Anadkat MJ, Chen ST, Fox LP, Harp J, Micheletti RG, Nambudiri VE, Pasieka HB, Shinohara MM, Rosenbach M, Merola JF Journal of the American Academy of Dermatology 2020 Oct 83 1150-1159 -
Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study
Schneeweiss MC, Perez Chada L, Gottlieb AB, Merola JF British Journal of Dermatology 2020 Sep 183 564-566 -
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry
Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, Mason M, Guo N, McLean RR, Greenberg JD, Van Voorhees AS Journal of the European Academy of Dermatology and Venereology 2020 Sep 34 2051-2058 -
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey
Tillett W, Merola JF, Thaçi D, Holdsworth E, Booth N, Lobosco LS, Milligan G, Hufford MM, Birt JA, Boehncke WH Rheumatology and Therapy 2020 Sep 7 617-637 -
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence (Dermatology and Therapy, (2020), 10, 3, (351-364), 10.1007/s13555-020-00373-z)
Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M Dermatology and Therapy 2020 Aug 10 901 -
Indoor tanning use is associated with psoriasis in the Nurses’ Health Study II
Choong CK, Merola JF, Han J, Li X British Journal of Dermatology 2020 Aug 183 384-386 -
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
Rich P, Goldblum O, Disch D, Lin CY, Merola JF, Elewski B Journal of Drugs in Dermatology 2020 Aug 19 741-746 -
Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus
Elman SA, Joyce C, Braudis K, Chong BF, Fernandez AP, Furukawa F, Hasegawa M, Kim HJ, Li SJ, Lian CG, Szepietowski JC, Werth VP, Merola JF JAMA Dermatology 2020 Aug 156 901-906 -
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis
Merola JF, Ghislain PD, Dauendorffer JN, Potts Bleakman A, Brnabic AJ, Burge R, Riedl E Journal of the European Academy of Dermatology and Venereology 2020 Jun 34 1257-1262 -
Report of the skin research workgroups from the grappa 2019 annual meeting
Perez-Chada LM, Merola JF, Armstrong AW, Gottlieb AB Journal of Rheumatology 2020 Jun 96 36-40 -
Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M Dermatology and Therapy 2020 Jun 10 351-364 -
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative
Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW American Journal of Clinical Dermatology 2020 Jun 21 323-338 -
Methotrexate in psoriasis and psoriatic arthritis
Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC Journal of Rheumatology 2020 Jun 96 31-35 -
Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study
Schneeweiss MC, Huang JT, Wyss R, Schneeweiss S, Merola JF Journal of the American Academy of Dermatology 2020 Jun 82 1337-1345 -
Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis from 3 Tertiary Care Centers
Tkachenko E, Steuer AB, Lo K, Lachance A, Merola JF, Femia AN, Vleugels RA JAMA Dermatology 2020 May 156 595-597 -
Comorbidities associated with psoriatic arthritis: Review and update
Perez-Chada LM, Merola JF Clinical Immunology 2020 May 214 -
Relationship between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study
Skougaard M, Jørgensen TS, Rifbjerg-Madsen S, Coates LC, Egeberg A, Amris K, Dreyer L, Højgaard P, Guldberg-Møller J, Merola JF, Frederiksen P, Gudbergsen H, Kristensen LE Journal of Rheumatology 2020 Apr 47 548-552 -
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary
Haberman R, Perez-Chada LM, Siegel E, Reginato AM, Webster D, Chandran V, Walsh J, Rosen CF, Reddy S, Ogdie A, Scher JU, Merola JF Journal of Psoriasis and Psoriatic Arthritis 2020 Apr 5 68-72 -
Risk of Inflammatory Arthritis after a New Diagnosis of Hidradenitis Suppurativa
Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF JAMA Dermatology 2020 Mar 156 342-345 -
Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review
Perez-Chada LM, Balak D, Cohen JM, Ogdie A, Merola JF, Gottlieb AB Expert review of clinical immunology 2020 Mar 16 267-283 -
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, Ink B, McInnes IB The Lancet 2020 Feb 395 427-440 -
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast
Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB American Journal of Clinical Dermatology 2020 Feb 21 109-117 -
Developing classification criteria for skin-predominant dermatomyositis: the Delphi process
Author Collaboration TS, Concha JS, Pena S, Gaffney RG, Patel B, Tarazi M, Kushner CJ, Merola JF, Fiorentino D, Dutz JP, Goodfield M, Nyberg F, Volc-Platzer B, Fujimoto M, Ang CC, Werth VP, Abuav R, Aggarwal R, Avashia-Khemka N, Callen JP, Cardones AR, Chisolm SS, Chong BF, Chung L, Clarke JT, Kari Connolly M, Costner M, Curran M, Dourmishev L, Drage LA, Femia AN, Fernandez AP, Fett N, Foulke G, Franks AG, Haemel A, Hamaguchi Y, Hansen CB, Imadojemu S, Jia Ker K, Kim HJ, Kurtzman DJ, Lam C, Laumann AE, Lin J, Mailhot JD, Meggitt SJ, Micheletti RG, Motegi Si, Muro Y, O'Brien E British Journal of Dermatology 2020 Feb 182 410-417 -
Treatment mode preferences in psoriatic arthritis: A qualitative multi-country study
Aletaha D, Elaine Husni M, Merola JF, Ranza R, Bertheussen H, Lippe R, Young PM, Cappelleri JC, Michelle Brown T, Ervin C, Hsu MA, Fallon L Patient Preference and Adherence 2020 14 949-961 -
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials
Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF Journal of the American Academy of Dermatology 2020 Jan 82 54-61 -
Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study
Elman SA, Joyce C, Costenbader KH, Merola JF Clinical and Experimental Dermatology 2020 Jan 45 89-91 -
An Approach to Retiform Purpura for the Inpatient Dermatologist
Alsarheed A, Cobos GA, Cornejo CM, Vleugels RA, Merola JF Current Dermatology Reports 2019 Dec 8 245-257 -
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: A post hoc analysis of two randomised controlled studies
Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaci D Annals of the Rheumatic Diseases 2019 Sep 78 1215-1219 -
Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis
Gottlieb AB, Germino R, Herrera V, Meng X, Merola JF Dermatology 2019 Jul 235 348-353 -
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation
Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF Journal of the American Academy of Dermatology 2019 Jul 81 102-110 -
SEAM-PsA: Seems Like Methotrexate Works in Psoriatic Arthritis?
Merola JF, Ogdie A Arthritis and Rheumatology 2019 Jul 71 1027-1029 -
TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management
Li SJ, Perez-Chada LM, Merola JF Journal of Psoriasis and Psoriatic Arthritis 2019 Apr 4 70-80 -
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N Journal of Clinical Investigation 2019 Mar 129 1359-1371 -
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Scher JU, Ogdie A, Merola JF, Ritchlin C Nature Reviews Rheumatology 2019 Mar 15 153-166 -
A provider global assessment quality measure for clinical practice for inflammatory skin disorders
Author Collaboration ID, Gottlieb A, Salame N, Armstrong AW, Merola JF, Parra S, Takeshita J, Chen SC, Latella J, Van Beek M Journal of the American Academy of Dermatology 2019 Mar 80 823-828 -
Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey
Merola JF, Shrom D, Eaton J, Dworkin C, Krebsbach C, Shah-Manek B, Birt J Rheumatology and Therapy 2019 Mar 6 33-45 -
Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity
Murage MJ, Anderson A, Casso D, Oliveria SA, Ojeh CK, Muram TM, Merola JF, Zbrozek A, Araujo AB Journal of Dermatological Treatment 2019 Feb 30 141-149 -
Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value
Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A Journal of Rheumatology 2019 Feb 46 160-165 -
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations
Concha JS, Patsatsi A, Marshak-Rothstein A, Liu Ml, Sinha AA, Lee LA, Merola JF, Jabbari A, Gudjonsson JE, Chasset F, Jarrett P, Chong B, Arkin L, Fernandez AP, Caproni M, Greenberg SA, Kim HJ, Pearson DR, Femia A, Vleugels RA, Fiorentino D, Fujimoto M, Wenzel J, Werth VP Journal of Investigative Dermatology 2019 Feb 139 270-276 -
Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment
Author Collaboration AA, Albrecht J, Adamson AS, Barbieri JS, Bennett DD, Kiracofe EA, Kourosh AS, Leslie KS, Merola JF, Nguyen J, Siegfried E, Strickland N, Olbricht S, Asgari MM Journal of the American Academy of Dermatology 2019 Feb 80 577-578 -
Plasma levels of tumour necrosis factor-α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
Johnson CM, Fitch K, Merola JF, Han J, Qureshi AA, Li WQ British Journal of Dermatology 2019 181 379-380 -
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J Arthritis Care and Research 2019 Jan 71 2-29 -
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J Arthritis and Rheumatology 2019 Jan 71 5-32 -
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J Journal of Psoriasis and Psoriatic Arthritis 2019 Jan 4 31-58 -
Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study
de Vlam K, Merola JF, Birt JA, Sandoval DM, Lobosco S, Moon R, Milligan G, Boehncke WH Rheumatology and Therapy 2018 Dec 5 423-436 -
Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics
Haberman R, Perez-Chada LM, Merola JF, Scher J, Ogdie A, Reddy SM Current Rheumatology Reports 2018 Dec 20 -
Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative
Perez-Chada LM, Cohen JM, Gottlieb AB, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF Archives of Dermatological Research 2018 Nov 310 701-710 -
Are your patients satisfied a systematic review of treatment satisfaction measures in psoriasis
Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW Dermatology 2018 Nov 234 157-165 -
Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA
Merola JF, Herrera V, Palmer JB Clinical Rheumatology 2018 Oct 37 2751-2761 -
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
Author Collaboration tI, Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A British Journal of Dermatology 2018 Oct 179 844-852 -
Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials
Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW JAMA Dermatology 2018 Oct 154 1237-1244 -
Patient-reported outcome measures for pediatric psoriasis: A systematic review and critical appraisal from international dermatology outcome measures (IDEOM)
Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW Dermatology 2018 Sep 234 112-119 -
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
Author Collaboration ob, Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GB British Journal of Dermatology 2018 Sep 179 642-650 -
Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice
Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A Journal of Investigative Dermatology 2018 Sep 138 1955-1961 -
Targeted therapies for psoriatic arthritis: An update for the dermatologist
Elman SA, Weinblatt ME, Merola JF Seminars in cutaneous medicine and surgery 2018 Sep 37 173-181 -
Distinguishing rheumatoid arthritis from psoriatic arthritis
Merola JF, Espinoza LR, Fleischmann R RMD Open 2018 Aug 4 -
Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity
Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB Journal of Medical Economics 2018 Aug 21 745-754 -
Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis
Lockshin B, Balagula Y, Merola JF Journal of the American Academy of Dermatology 2018 Aug 79 345-352 -
Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation a systematic review
Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM, Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW JAMA Dermatology 2018 Aug 154 934-950 -
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Papp KA, Merola JF, Gottlieb AB, Griffiths CE, Cross N, Peterson L, Cioffi C, Blauvelt A Journal of the American Academy of Dermatology 2018 Aug 79 277-286.e10 -
Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation
Zhang A, Kurtzman DJ, Perez-Chada LM, Merola JF Clinics in Dermatology 2018 Jul 36 551-560 -
Inflammatory arthritis and crystal arthropathy: Current concepts of skin and systemic manifestations
Fazel M, Merola JF, Kurtzman DJ Clinics in Dermatology 2018 Jul 36 533-550 -
Report of the skin research workgroups from the GRAPPA 2018 annual meeting
Perez-Chada LM, Merola JF, Armstrong AW, Gottlieb AB Journal of Rheumatology 2018 Jun 95 28-32 -
Polyarthralgias and Papulonodules in a 56-Year-Old Woman
Singer SB, Thomas C, Lezcano C, Robbins M, Gordian A, Nori S, Granter SR, Merola JF, O'Malley JT Arthritis Care and Research 2018 Jun 70 925-930 -
GRAPPA 2017 project report
Duffin KC, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC Journal of Rheumatology 2018 Jun 94 48-51 -
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole
Dewan AK, Pinard J, Jadeja S, Granter S, Merola JF Clinical and Experimental Dermatology 2018 Jun 43 494-496 -
Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis
Song P, Fett NM, Lin J, Merola JF, Costner M, Vleugels RA British Journal of Dermatology 2018 Jun 178 1412-1415 -
Report of the skin research working groups from the GRAPPA 2017 annual meeting
Gottlieb AB, Coates LC, Van Mens LJ, Armstrong AW, Merola JF Journal of Rheumatology 2018 Jun 94 40-43 -
Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails
Merola JF, Qureshi A, Husni ME Dermatologic Therapy 2018 May 31 -
Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004–2015
Lee MP, Lii J, Jin Y, Desai RJ, Solomon DH, Merola JF, Kim SC Arthritis Care and Research 2018 May 70 791-796 -
Wounds That Would Not Heal: Pyoderma Gangrenosum
Pinard J, Chiang DY, Mostaghimi A, Granter SR, Merola JF, Barkoudah E American Journal of Medicine 2018 Apr 131 377-379 -
Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis
Concha JS, Merola JF, Fiorentino D, Werth VP Journal of the American Academy of Dermatology 2018 Apr 78 769-775.e2 -
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS Arthritis and Rheumatology 2018 Mar 70 345-355 -
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II
Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, Bechara FG, Cohen AD, Daham N, Davis M, Emtestam L, Fernández-Peñas P, Filippelli M, Gibbons A, Grant T, Guilbault S, Gulliver S, Harris C, Harvent C, Houston K, Kirby JS, Matusiak L, Mehdizadeh A, Mojica T, Okun M, Orgill D, Pallack L, Parks-Miller A, Prens EP, Randell S, Rogers C, Rosen CF, Choon SE, van der Zee HH, Christensen R, Jemec GB British Journal of Dermatology 2018 Mar 178 715-721 -
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS Journal of the American Academy of Dermatology 2018 Feb 78 383-394 -
Subacute cutaneous lupus erythematosus induced by palbociclib
Pinard J, Patel M, Granter SR, Vleugels RA, Merola JF Journal of Cutaneous Medicine and Surgery 2018 Jan 22 341-343 -
Lupus community panel proposals for optimising clinical trials: 2018
Merrill JT, Manzi S, Aranow C, Askenase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP Lupus Science and Medicine 2018 5 -
Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire
Pinard J, Vleugels RA, Joyce C, Merola JF, Patel M Journal of the American Academy of Dermatology 2018 Jan 78 215-217.e2 -
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data
Gottlieb AB, Merola JF, Chen R, Levi E, Duffin KC Journal of the American Academy of Dermatology 2017 Dec 77 1178-1180 -
The psychosocial burden of psoriatic arthritis
Husni ME, Merola JF, Davin S Seminars in Arthritis and Rheumatism 2017 Dec 47 351-360 -
Novel posterior auricular cutaneous reaction after anti–TNF-α infusion in young women with Crohn's disease
Ko LN, Pinard J, Merola JF, Patel M JAAD Case Reports 2017 Nov 3 512-514 -
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects
Author Collaboration tI, Author Collaboration PR, Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruc PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, De la Torre IG, Reed AM, Song YW, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J, Aggarwal R, Christopher-Stine L, Criscione-Schreiber L, Crofford L, Cronin ME, Gordon P, Hengstman G, Katz JD, Mammen A, Marder G, McHugh N, Schiopu E, Wolfe G, Wortmann R, Apaz M, Bowyer S, Constantin T, Curran M, Davidson J, Punaro M, Merola J Rheumatology (United Kingdom) 2017 Nov 56 1884-1893 -
Tofacitinib or adalimumab versus placebo for psoriatic arthritis
Mease P, Hall S, FitzGerald O, Van Der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS New England Journal of Medicine 2017 Oct 377 1537-1550 -
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K Journal of the European Academy of Dermatology and Venereology 2017 Oct 31 1686-1692 -
Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus
Fruchter R, Kurtzman DJ, Patel M, Merola J, Franks AG, Vleugels RA, Femia AN JAMA Dermatology 2017 Sep 153 937-939 -
Intralesional sodium thiosulfate treatment for calcinosis cutis in the setting of lupus panniculitis
Gunasekera NS, Gracey Maniar LE, Lezcano C, Laga AC, Merola JF JAMA Dermatology 2017 Sep 153 944-945 -
The static physician's global assessment of genitalia: A clinical outcome measure for the severity of genital psoriasis
Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, Guenther L, Sullivan J, Meeuwis K, See K, Duffin KC Journal of Drugs in Dermatology 2017 Aug 16 793-799 -
Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)
Schneeweiss M, Merola JF, Karlson EW, Solomon DH BMC Dermatology 2017 Aug 17 -
Switching biologics in the treatment of psoriatic arthritis
Merola JF, Lockshin B, Mody EA Seminars in Arthritis and Rheumatism 2017 Aug 47 29-37 -
Treatment of inverse/intertriginous psoriasis: Updated guidelines from the medical board of the national psoriasis foundation
Khosravi H, Siegel MP, Van Voorhees AS, Merola JF Journal of Drugs in Dermatology 2017 Aug 16 760-766 -
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting summary and data from the psoriasis working group
Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW, Merola JF Journal of Drugs in Dermatology 2017 Aug 16 770-777 -
Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise
Elman SA, Joyce C, Nyberg F, Furukawa F, Goodfield M, Hasegawa M, Marinovic B, Szepietowski JC, Dutz J, Werth VP, Merola JF Journal of the American Academy of Dermatology 2017 Aug 77 261-267 -
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M Journal of the American Academy of Dermatology 2017 Jul 77 79-87.e1 -
Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) survey: Benefits and challenges of combined rheumatology-dermatology clinics
Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF Journal of Rheumatology 2017 May 44 693-694 -
Polyphenotypic psoriasis: A report from the GRAPPA 2016 annual meeting
Kaskas N, Merola JF, Qureshi AA, Paek SY Journal of Rheumatology 2017 May 44 695-696 -
Defining outcome measures for psoriasis: The IDEOM report from the GRAPPA 2016 annual meeting
Duffin KC, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW Journal of Rheumatology 2017 May 44 701-702 -
Practical assessment of psoriasis clinical severity in both clinical trials and clinical practice settings: A report from the GRAPPA 2016 annual meeting
Merola JF, Gottlieb AB Journal of Rheumatology 2017 May 44 691-692 -
Benchmarking care in psoriatic arthritis - The QUANTUM report: A report from the GRAPPA 2016 annual meeting
Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS Journal of Rheumatology 2017 May 44 674-678 -
Classifying discoid lupus erythematosus: background, gaps, and difficulties
Haber JS, Merola JF, Werth VP International Journal of Women's Dermatology 2017 Mar 3 S62-S66 -
The International Dermatology Outcome Measures (IDEOM) initiative: A review and update
Elman SA, Merola JF, Armstrong AW, Duffin KC, Latella J, Garg A, Gottlieb AB Journal of Drugs in Dermatology 2017 Feb 16 119-124 -
Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes
Thorlacius L, Ingram JR, Garg A, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Christensen R, Jemec GB BMJ Open 2017 Feb 7 -
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Bagel J, Weinberg JM, Williams MJ, Wu JJ, Yamauchi PS, Van Voorhees AS Journal of the American Academy of Dermatology 2017 Feb 76 290-298 -
Tofacitinib citrate for refractory cutaneous dermatomyositis: An alternative treatment
Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, Vleugels RA JAMA Dermatology 2016 Aug 152 944-945 -
Shedding light on the "hidden psoriasis": A pilot study of the inverse psoriasis burden of disease (IPBOD) questionnaire
Cohen JM, Halim K, Joyce CJ, Patel M, Qureshi AA, Merola JF Journal of Drugs in Dermatology 2016 Aug 15 1011-1016 -
Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis
Timerman D, Devlin PM, Nambudiri VE, Wright NA, Vleugels RA, Clark RA, Kupper TS, Merola JF, Patel M Clinical and Experimental Dermatology 2016 Jul 41 498-501 -
Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology
Elman SA, Merola JF Journal of Investigative Dermatology 2016 Jul 136 1325-1329 -
Prevalence of psoriasis phenotypes among men and women in the USA
Merola JF, Li T, Li WQ, Cho E, Qureshi AA Clinical and Experimental Dermatology 2016 Jul 41 486-489 -
Developing classification criteria for discoid lupus erythematosus: An update from the World Congress of Dermatology 2015 meeting
Elman SA, Nyberg F, Furukawa F, Goodfield M, Hasegawa M, Marinovic B, Szepietowski J, Dutz J, Werth VP, Merola JF International Journal of Women's Dermatology 2016 Jun 2 44-45 -
International dermatology outcome measures initiative as applied to psoriatic disease outcomes: An update
Merola JF, Armstrong AW, Saraiya A, Latella J, Garg A, Duffin KC, Gottlieb AB Journal of Rheumatology 2016 May 43 959-960 -
Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting
Paek SY, Thompson JM, Qureshi AA, Merola JF, Elaine Husni M Journal of Rheumatology 2016 May 43 961-964 -
The psoriatic disease payer advisory panel
Greb JE, Merola J, Garg A, Latella J, Howard L, Acharya N, Gottlieb AB Journal of Drugs in Dermatology 2016 May 15 641-644 -
Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects
Xue Y, Cohen JM, Wright NA, Merola JF American Journal of Clinical Dermatology 2016 Apr 17 147-162 -
Classifying discoid lupus erythematosus: background, gaps, and difficulties
Haber JS, Merola JF, Werth VP International Journal of Women's Dermatology 2016 Mar 2 8-12 -
Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature
Sheu JS, Divito SJ, Enamandram M, Merola JF Dermatology 2016 Feb 232 97-101 -
Histopathology of the Inner Ear in a Case with Recent Onset of Cogan's Syndrome: Evidence for Vasculitis
Jung DH, Nadol JB, Folkerth RD, Merola JF Annals of Otology, Rhinology and Laryngology 2016 Jan 125 20-24 -
Dapsone for treatment of erythema nodosum
Song JS, Halim K, Vleugels RA, Merola JF Dermatology online journal 2016 22 -
Epidemiology and treatment of eosinophilic fasciitis: An analysis of 63 patients from 3 tertiary care centers
Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA JAMA Dermatology 2016 Jan 152 97-99 -
Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center Components of this work were presented at the 2014 Medical Dermatology Society Meeting in Denver, CO, on March 20, 2014, and at the 2014 Society for Investigative Dermatology Meeting in Albuquerque, NM, on May 9, 2014.
Patel M, Cohen JM, Wright NA, Merola JF, Qureshi AA, Vleugels RA Journal of the American Academy of Dermatology 2015 Oct 73 701-702 -
Mosaic focal dermal hypoplasia caused by a novel somatic mutation in PORCN detected in affected skin
Sheu J, Divito SJ, Hoffman EP, Frank NY, Merola JF British Journal of Dermatology 2015 Aug 173 568-570 -
Psoriasis, psoriatic arthritis and risk of gout in US men and women
Merola JF, Wu S, Han J, Choi HK, Qureshi AA Annals of the Rheumatic Diseases 2015 Aug 74 1495-1500 -
A man with fever, cough, and rash
Geller BJ, Stone RM, Merola JF, Levy BD, Loscalzo J New England Journal of Medicine 2015 Jul 373 74-80 -
Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists
Goyal A, Goyal K, Merola JF American Journal of Clinical Dermatology 2015 Jun 16 179-195 -
Redefining cutaneous lupus erythematosus: A proposed international consensus approach and results of a preliminary questionnaire
Merola JF, Nyberg F, Furukawa F, Goodfield MJ, Hasegawa M, Marinovic B, Szepietowski J, Dutz J, Werth VP Lupus Science and Medicine 2015 Jun 2 -
A comprehensive assessment tool for psoriasis ' an unmet need: Report from the GRAPPA 2014 annual meeting
Cohen JM, Qureshi AA, Merola JF Journal of Rheumatology 2015 Jun 42 1032-1033 -
Psoriatic arthritis: It's as easy as "PSA"
Cohen JM, Husni ME, Qureshi AA, Merola JF Journal of the American Academy of Dermatology 2015 May 72 905-906 -
Myeloperoxidase-antineutrophil cytoplasmic antibodies (mpo-anca) and proteinase 3-anca without immunofluorescent ANCA found by routine clinical testing
Rao DA, Wei K, Merola JF, O'Brien WR, Takvorian SU, Dellaripa PF, Schur PH Journal of Rheumatology 2015 May 42 847-852 -
Treatment of coexistent psoriasis and lupus erythematosus
Varada S, Gottlieb AB, Merola JF, Saraiya AR, Tintle SJ Journal of the American Academy of Dermatology 2015 72 253-260 -
The international dermatology outcome measures group: Formation of patient-centered outcome measures in dermatology
Gottlie AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, Garg A, Merola JF, Maccarone M, Christensen R Journal of the American Academy of Dermatology 2015 72 345-348 -
Eosinophilic fasciitis-like disorder developing in the setting of multiple sclerosis therapy
Sheu J, Kattapuram SV, Stankiewicz JM, Merola JF Journal of Drugs in Dermatology 2014 Sep 13 1144-1147 -
Clinical manifestations and survival among adults with (SLE) according to age at diagnosis
Merola JF, Bermas B, Lu B, Karlson EW, Massarotti E, Schur PH, Costenbader KH Lupus 2014 Jul 23 778-784 -
The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A novel index to measure all non-plaque psoriasis subsets
Patel M, Liu SW, Qureshi A, Merola JF Journal of Rheumatology 2014 Jun 41 1230-1232 -
The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting
Gottlieb AB, Armstrong AW, Christensen R, Garg A, Duffin KC, Boehncke WH, Merola JF, Gladman DD, Mease PJ, Swerlick RA, Rosen CF, Abernethy A Journal of Rheumatology 2014 Jun 41 1227-1229 -
Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus
Takvorian SU, Merola JF, Costenbader KH Lupus 2014 May 23 537-544 -
No association between vitamin D intake and incident psoriasis among US women
Merola JF, Han J, Li T, Qureshi AA Archives of Dermatological Research 2014 Apr 306 305-307 -
Psoriatic arthritis screening tools: Study design and methodological challenges
Merola JF, Husni ME, Qureshi AA British Journal of Dermatology 2014 170 994-995 -
Diagnosing and treating psoriatic arthritis: An update
Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb AB British Journal of Dermatology 2014 170 772-786 -
Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity
Frankel HC, Sharon VR, Vleugels RA, Merola JF, Qureshi AA International Journal of Dermatology 2013 Nov 52 1407-1409 -
Lupus erythematosus panniculitis-induced facial atrophy: Effective treatment with poly-L-lactic acid and hyaluronic acid dermal fillers
Eastham AB, Liang CA, Femia AN, Lee TC, Vleugels RA, Merola JF Journal of the American Academy of Dermatology 2013 Nov 69 e260-e262 -
Psoriasiform reactions to anti-tumor necrosis factor α therapy
Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA Journal of Clinical Rheumatology 2013 Oct 19 377-381 -
Intravenous immunoglobulin for refractory cutaneous dermatomyositis: A retrospective analysis from an academic medical center
Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA Journal of the American Academy of Dermatology 2013 Oct 69 654-657 -
Screening instruments for psoriatic arthritis
Merola JF, Husni ME, Qureshi AA Journal of Rheumatology 2013 Sep 40 1623 -
Lupus-like syndromes related to drugs
Merola JF 2013 Sep 211-221 -
Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus
Merola JF, Prystowsky SD, Iversen C, Gomez-Puerta JA, Norton T, Tsao P, Massarotti E, Schur P, Bermas B, Costenbader KH Journal of the American Academy of Dermatology 2013 Jul 69 19-24 -
Apremilast for discoid lupus erythematosus: Results of a phase 2, open-label, single-arm, pilot study
De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Journal of Drugs in Dermatology 2012 Oct 11 1224-1226 -
At a loss
Merola JF, Ghoroghchian PP, Samuels MA, Levy BD, Loscalzo J New England Journal of Medicine 2012 Jul 367 67-72 -
At a loss
Vaidya A, Ghoroghchian PP, Merola JF, Samuels MA New England Journal of Medicine 2012 Jun 366 e37 -
Hidradenitis suppurativa resulting in systemic amyloid a amyloidosis: A case report and review of the literature
Girouard SD, Falk RH, Rennke HG, Merola JF Dermatology online journal 2012 Jan 18 -
Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus?
Merola JF, Chang CA, Sanchez MR, Prystowsky SD Journal of Drugs in Dermatology 2011 Dec 10 1413-1420 -
Part III: B. Levamisole-induced retiform purpura
Click J, Gee S, Cortes R, Gedmintas L, Merola JF, Bykerk V, Saveedra A Journal of Drugs in Dermatology 2011 Feb 10 217 -
Generalized discoid lupus erythematosus
Farley-Loftus R, Mahlberg M, Merola JF, Votava HJ, Meehan S, Stein J, Shupack JL Dermatology online journal 2009 Aug 15 -
Familial benign chronic pemphigus (Hailey-Hailey disease)
Warycha M, Patel R, Meehan S, Merola JF Dermatology online journal 2009 Aug 15 -
Raynaud's phenomenon: Pathogenesis and management
Bakst R, Merola JF, Franks AG, Sanchez M Journal of the American Academy of Dermatology 2008 Oct 59 633-653 -
Exogenous ochronosis
Merola JF, Meehan S, Walters RF, Brown L Dermatology online journal 2008 Oct 14 -
Cutaneous Rosai-Dorfman disease
Merola JF, Pulitzer M, Rosenman K, Brownell I Dermatology online journal 2008 May 14 -
Eruptive xanthomas
Merola JF, Mengden SJ, Soldano A, Rosenman K Dermatology online journal 2008 May 14
-
Psoriasis
Research
- Psoriasis, psoriatic arthritis
- Cutaneous and systemic lupus erythematosus
- Atopic dermatitis
- Connective tissue disease and autoimmune skin diseases
- Clinical trials, clinical trial design
- Pharmacoepidemiology
- Outcome measures development, validation
Clinical Focus
- Psoriasis, Psoriatic Arthritis, and Spondyloarthritis
- Connective Tissue Disease
- Atopic Dermatitis
- Lupus
- Dermatomyositis
- Systemic Sclerosis
- Complex Medical Dermatology
Links
- Dr. Merola’s publications | PubMed
- Sweet’s syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis | UpToDate
- Sweet’s syndrome (acute febrile neutrophilic dermatosis): Management and prognosis | UpToDate
- Drug-induced lupus | UpToDate
- Cutaneous lupus overview | UpToDate
- SAPHO syndrome | UpToDate